Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ports, Prosthetics Take Blame In Partial Hold For Aduro’s Immunotherapy Trials

Executive Summary

Aduro hopes for a relatively quick resolution to a clinical hold for its LADD cancer vaccine studies instituted by the FDA based on listeria detected around indwelling ports in two patients.

Advertisement

Related Content

Merck Expands Aduro Collaboration In Keytruda Tie-Up
Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost
Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up
Stockwatch: Fireworks Or Ballistic Missiles In Biotechnology?
Zika Vaccine Timeline: Will It Be Too Little Too Late?
Advaxis Sinks On Delayed Disclosure Of Clinical Hold

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel